A business in context
TVTX research notebook
Read the disclosures. Follow the relationships. Keep the dates in view.
Filing timeline
Download filings CSVReported insider transactions
Download transactions CSVP · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
| Transaction / filed | Reporting owner | Type | Security | Shares | Reported price |
|---|---|---|---|---|---|
| 2026-09-17 | Heerma Peter | M · Exercise / conversion | Common Stock | 8282.0 | 22.4 |
| 2026-09-17 | Heerma Peter | S · Sale | Common Stock | 8282.0 | 65.07 |
| 2026-09-17 | Heerma Peter | M · Exercise / conversion | Employee stock option (right to buy) | 8282.0 | 0.0 |
| 2026-09-17 | Dube Eric M | S · Sale | Common Stock | 6802.0 | 64.95 |
| 2026-09-17 | Dube Eric M | M · Exercise / conversion | Common Stock | 108493.0 | 23.34 |
| 2026-09-17 | Dube Eric M | S · Sale | Common Stock | 101691.0 | 64.59 |
| 2026-09-17 | Dube Eric M | M · Exercise / conversion | Employee stock option (right to buy) | 108493.0 | 0.0 |
| 2026-09-16 | Heerma Peter | M · Exercise / conversion | Common Stock | 55000.0 | 15.46 |
| 2026-09-16 | Heerma Peter | M · Exercise / conversion | Common Stock | 17717.0 | 26.88 |
| 2026-09-16 | Heerma Peter | S · Sale | Common Stock | 93604.0 | 63.25 |
| 2026-09-16 | Heerma Peter | S · Sale | Common Stock | 79113.0 | 63.65 |
| 2026-09-16 | Heerma Peter | M · Exercise / conversion | Common Stock | 100000.0 | 11.25 |
| 2026-09-16 | Heerma Peter | M · Exercise / conversion | Employee stock option (right to buy) | 17717.0 | 0.0 |
| 2026-09-16 | Heerma Peter | M · Exercise / conversion | Employee stock option (right to buy) | 55000.0 | 0.0 |
| 2026-09-16 | Heerma Peter | M · Exercise / conversion | Employee stock option (right to buy) | 100000.0 | 0.0 |
| 2026-09-16 | Dube Eric M | S · Sale | Common Stock | 99716.0 | 63.26 |
| 2026-09-16 | Dube Eric M | S · Sale | Common Stock | 96125.0 | 63.64 |
| 2026-09-16 | Dube Eric M | M · Exercise / conversion | Common Stock | 195841.0 | 23.34 |
| 2026-09-16 | Dube Eric M | M · Exercise / conversion | Employee stock option (right to buy) | 195841.0 | 0.0 |
| 2026-09-16 | ROTE WILLIAM E. | M · Exercise / conversion | Common Stock | 350.0 | 17.96 |
| 2026-09-16 | ROTE WILLIAM E. | M · Exercise / conversion | Common Stock | 55000.0 | 15.46 |
| 2026-09-16 | ROTE WILLIAM E. | M · Exercise / conversion | Common Stock | 57500.0 | 26.88 |
| 2026-09-16 | ROTE WILLIAM E. | S · Sale | Common Stock | 65104.0 | 63.12 |
| 2026-09-16 | ROTE WILLIAM E. | S · Sale | Common Stock | 47746.0 | 63.61 |
| 2026-09-16 | ROTE WILLIAM E. | M · Exercise / conversion | Employee stock option (right to buy) | 57500.0 | 0.0 |
| 2026-09-16 | ROTE WILLIAM E. | M · Exercise / conversion | Employee stock option (right to buy) | 55000.0 | 0.0 |
| 2026-09-16 | ROTE WILLIAM E. | M · Exercise / conversion | Employee stock option (right to buy) | 350.0 | 0.0 |
| 2026-09-15 | Cline Christopher R. | S · Sale | Common Stock | 27473.0 | 62.0 |
| 2026-09-15 | Cline Christopher R. | M · Exercise / conversion | Common Stock | 20000.0 | 17.44 |
| 2026-09-15 | Cline Christopher R. | S · Sale | Common Stock | 400.0 | 65.31 |
| 2026-09-15 | Cline Christopher R. | S · Sale | Common Stock | 20735.0 | 62.61 |
| 2026-09-15 | Cline Christopher R. | S · Sale | Common Stock | 1900.0 | 63.69 |
| 2026-09-15 | Cline Christopher R. | M · Exercise / conversion | Employee stock option (right to buy) | 20000.0 | 0.0 |
| 2026-09-15 | Inrig Jula | M · Exercise / conversion | Common Stock | 32395.0 | 8.93 |
| 2026-09-15 | Inrig Jula | S · Sale | Common Stock | 25390.0 | 62.02 |
| 2026-09-15 | Inrig Jula | S · Sale | Common Stock | 400.0 | 65.31 |
| 2026-09-15 | Inrig Jula | S · Sale | Common Stock | 1600.0 | 63.69 |
| 2026-09-15 | Inrig Jula | S · Sale | Common Stock | 17284.0 | 62.62 |
| 2026-09-15 | Inrig Jula | M · Exercise / conversion | Employee stock option (right to buy) | 32395.0 | 0.0 |
| 2026-09-15 | Calvin Sandra | M · Exercise / conversion | Common Stock | 2500.0 | 27.5 |
| 2026-09-15 | Calvin Sandra | M · Exercise / conversion | Common Stock | 1250.0 | 22.4 |
| 2026-09-15 | Calvin Sandra | S · Sale | Common Stock | 300.0 | 63.66 |
| 2026-09-15 | Calvin Sandra | S · Sale | Common Stock | 4275.0 | 62.14 |
| 2026-09-15 | Calvin Sandra | S · Sale | Common Stock | 800.0 | 62.85 |
| 2026-09-15 | Calvin Sandra | M · Exercise / conversion | Common Stock | 1625.0 | 20.46 |
| 2026-09-15 | Calvin Sandra | M · Exercise / conversion | Employee stock option (right to buy) | 1625.0 | 0.0 |
| 2026-09-15 | Calvin Sandra | M · Exercise / conversion | Employee stock option (right to buy) | 2500.0 | 0.0 |
| 2026-09-15 | Calvin Sandra | M · Exercise / conversion | Employee stock option (right to buy) | 1250.0 | 0.0 |
| 2026-09-15 | Heerma Peter | S · Sale | Common Stock | 1431.0 | 65.31 |
| 2026-09-15 | Heerma Peter | S · Sale | Common Stock | 1400.0 | 63.65 |
Identity & relationships
SEC issuer · 0001438533Travere Therapeutics, Inc.
Search names and former names
- Retrophin, Inc. · former SEC name · 2013-02-21 to 2020-11-13
- Desert Gateway, Inc. · former SEC name · 2008-06-27 to 2013-02-19
Revenue in constant purchasing power
| Year ended | Reported USD revenue | CPI-adjusted USD revenue |
|---|---|---|
| 2024-12-31 | $233.18M | $250.45M |
| 2023-12-31 | $145.24M | $160.59M |
| 2022-12-31 | $109.46M | $126.00M |
| 2021-12-31 | $131.84M | $163.91M |
| 2020-12-31 | $198.32M | $258.19M |
| 2019-12-31 | $175.34M | $231.07M |
| 2018-12-31 | $164.25M | $220.38M |
| 2017-12-31 | $154.94M | $212.97M |